Free shipping on all orders over $ 500

SC144

Cat. No. M3001

All AbMole products are for research use only, cannot be used for human consumption.

SC144 Structure
Size Price Availability Quantity
1mg USD 25 In stock
5mg USD 45 In stock
10mg USD 75 In stock
25mg USD 149 In stock
50mg USD 249 In stock
100mg USD 410 In stock
Free Delivery on orders over USD 500 Bulk Inquiry?

Quality Control & Documentation
Biological Activity

SC144 is the first oral active GP130 (IL6-beta) inhibitor. SC144 binds gp130, induces gp130 phosphorylation (S782) and deglycosylation, eliminates Stat3 phosphorylation and nuclear translocation, and further inhibits downstream target gene expression. SC144 inhibited signal transduction induced by GP130 ligand. SC144 induces apoptosis of human ovarian cancer cells.

Protocol (for reference only)
Cell Experiment
Cell lines OVCAR-8, OVCAR-5, OVCAR-3, Caov-3, SKOV-3, HEY NCI/ADR-RES
Preparation method MTT assay
Concentrations ~10 μM
Incubation time 96 h
Animal Experiment
Animal models Human Ovarian Cancer OVCAR-8 Xenograft
Formulation .9% NaCl with 40% propylene glycol
Dosages 10 mg/kg daily
Administration i.p. or p.o.
Chemical Information
Molecular Weight 322.3
Formula C16H11FN6O
CAS Number 895158-95-9
Form Solid
Solubility (25°C) DMSO 15 mg/mL
Storage Powder          -20°C   3 years ;  4°C   2 years
In solvent       -80°C   6 months ;  -20°C   1 month
References

[1] Tiangong Lu, et al. Up-regulation of hypoxia-inducible factor antisense as a novel approach to treat ovarian cancer

[2] Fedora Grande, et al. Identification and Preclinical Evaluation of SC144, a Novel Pyrroloquinoxaline Derivative with Broad-Spectrum Anticancer Activity

[3] Shili Xu, et al. Discovery of a novel orally active small-molecule gp130 inhibitor for the treatment of ovarian cancer

[4] Takashi Oshima, et al. Combination effects of SC144 and cytotoxic anticancer agents

[5] Carmen Plasencia, et al. Discovery of a novel quinoxalinhydrazide with a broad-spectrum anticancer activity

Related IL Receptor/Related Products
Reslizumab

Reslizumab (Sch 55700) is a humanized monoclonal antibody targeting human interleukin 5 (IL-5) for the study of eosinophilic asthma. Reslizumab effectively blocks il-5 function. Reslizumab inhibited IL-5-dependent cell proliferation with an IC50 of about 91.1 pM.

Montelukast sodium

Montelukast sodium selectively antagonizes leukotriene D 4 (LTD4) by binding to it so that block the action of leukotriene D4 on the cysteinyl leukotriene receptor CysLT1.

VGX-1027

VGX-1027 is an orally active immunomodulator.

Diacerein

Diacerin is an inhibitor of pro-inflammatory cytokine Interleukin-1B (IL-1B) production, prescribed for osteoarthritis and chronic inflammatory arthritis.

Suplatast Tosylate

Suplatast Tosilate is a novel capsular anti-asthmatic agent that suppresses both IgE production, IL-4 and IL-5 synthesis with IC50 above 100 μM.

  Catalog
Abmole Inhibitor Catalog




Keywords: SC144 supplier, IL Receptor/Related, inhibitors, activators

All AbMole products are for research use only, cannot be used for human consumption or veterinary use. We do not provide products or services to individuals. Please comply with the intended use and do not use AbMole products for any other purpose.



Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2026 AbMole BioScience. All Rights Reserved.